The Arabian Gulf is facing a high prevalence of hypertension , diabetes mellitus , smoking, and metabolic syndrome, which are the risk factors for cardiovascular disease (CVD). In addition, elevated levels of low-density lipoprotein-cholesterol (LDL-C), which is associated with four million deaths worldwide, are also high among people in the Middle East. Furthermore, the occurrence of familial hypercholesterolemia (FH) and the number of patients who failed to achieve LDL-C goals was also high in Middle Eastern countries.
However, evolocumab , a monoclonal antibody and proprotein convertase subtilisin/kexin type 9 inhibitor, has been shown to reduce LDL-C levels in patients. 1 Now, researchers from Saudi Arabia and Kuwait have investigated the safety and efficacy of evolocumab among 225 patients with hyperlipidemia in Saudi Arabia (n = 155) and Kuwait (n = 70). 2 The study It was part…
